Equities Analysts Issue Forecasts for Omeros FY2025 Earnings

Omeros Co. (NASDAQ:OMER) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Omeros in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will earn ($1.73) per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

OMER has been the topic of a number of other reports. Rodman & Renshaw began coverage on Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective on the stock. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Thursday, January 16th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Friday, January 17th. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Down 1.9 %

Shares of NASDAQ:OMER opened at $9.15 on Wednesday. The business has a 50-day moving average of $9.45 and a two-hundred day moving average of $6.07. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60.

Institutional Investors Weigh In On Omeros

Several hedge funds and other institutional investors have recently modified their holdings of OMER. Geode Capital Management LLC increased its holdings in shares of Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after purchasing an additional 6,839 shares during the period. State Street Corp grew its holdings in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after purchasing an additional 3,839 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares during the period. Rhumbline Advisers increased its position in shares of Omeros by 6.1% during the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after purchasing an additional 6,435 shares during the period. Finally, Barclays PLC raised its stake in shares of Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.